Over the past year, cardiologists on podcasts have mostly predicted that GLP-1 drugs will become heart drugs, not just weight-loss drugs, and that better, cheaper versions are on the way. Many attach a condition: the drugs will work best alongside diet and lifestyle change, and not everyone will be able to get them.

I searched transcripts from Nov 2025 to Nov 2026. I kept only lines spoken by guests who are cardiologists and that point to the future. Hosts' lines aren't included.

1. GLP-1s will become standard heart medicine

• Tara Narula on The Oprah Podcast: "Eventually, these, I think, may become… cardiac drugs, not weight loss drugs… if they're not overweight or obese, but they have cardiovascular disease… we might end up giving them a GLP." She compares this to how she prescribes a statin today. (listen)
• John Ostrominski on Cardionerds, about heart failure with preserved ejection fraction (HFpEF) and metabolic syndrome: "I would think very strongly about initiating either semaglutide or tirzepatide in this particular population." (listen)
• Faiez Zannad on EASL Podcasts is more cautious. He notes there's still no "compelling outcome trial" on heart-failure hospitalization and death, but with "multiple trials on the way," GLP-1s plus GIP drugs and other incretins "may be very helpful into mitigating the risk of HFpEF." (listen)

2. "This is the worst these drugs will ever be"

• Greg Katz on Future Pulse Cardiology made the most confident call, after the retatrutide trial results: "today, September 30th, 2026, this is the worst the GLP-1 drugs are going to be… I'm not convinced that Ozempic, Wegovy, Mounjaro, Zepbound have even come close to getting us all the cardiovascular benefit." (listen)
• Eric Topol on The Next Big Idea predicts the drugs that win "might not be the drugs we have today that are injectables and expensive." He also floats uses in Alzheimer's, cancer prevention and aging. (listen)

3. Generic Ozempic will cut prices and widen access

• Chris Labos on Montreal Now, speaking about Canada: the Ozempic patent "has expired," and "over the next few months, some of the generic manufacturers are going to start making generic versions." Diabetes doses come first, then obesity doses. "That price drop is going to make the government approval thing relatively moot." (listen)

4. A public-health turning point, if access is fair

• Robert Califf, former FDA commissioner (a cardiologist, no longer practicing), on The Life Science Rundown: "if we could equitably distribute this class of drugs… we could see a time where we reverse this chronic disease epidemic." (listen)
• Elizabeth Klodas on Healthcare NOW Radio: "GLP-1s are going to change medicine." She hopes they put "economic pressure on the food environment to change." (listen)
• John Deanfield on The Dokkcast says the drugs are "changing the opportunity to treat obesity in a remarkable way," but adds "it's not just a quick fix." (listen)

5. The skeptics: the drugs won't replace diet

• Dariush Mozaffarian on The Genius Life: "GLP-1s are terrific, but I don't think they're going to change the story of where we need to go." (listen)
• Bret Scher on Intelligent Medicine: staying on a drug for life is "kind of a recipe for failure." He sees the drugs as a kickstart, with lifestyle change as "an off ramp." (listen)
• Joel Kahn on The Other Side of Medicine: patients "have to go to a lifestyle management class to qualify to continue to get Ozempic and Wegovy and Zepbound and Mounjaro." (listen)

The overall picture: the most optimistic calls come from academic and preventive cardiologists: Katz, Narula, Topol and Califf. The doubts come mostly from lifestyle- and nutrition-focused cardiologists. Almost everyone hedges on the hard heart outcomes: how much the drugs cut heart failure, heart attacks and deaths is still waiting on trials.

A correction: the John Deanfield link in section 4 has a typo. Here is the correct one: listen to Deanfield on The Dokkcast.